DF/HCC Program Affiliation

Cancer Imaging

Research Abstract

Our laboratory is engaged in the development of transition-metal based radiopharmaceuticals for cancer imaging and therapy. The focus of the imaging program is on the development of Cu-64-based PET agents that can be used to non-invasively evaluate the multidrug resistance status of patients with breast and other types of cancer. These new copper complexes are, like the MDR chemotherapeutics, substrates for Pgp, the protein implicated in MDR1 multidrug resistance. We are also developing new antibody/chelate conjugates for use in attaching Cu-64 (and other diagnostic and therapeutic radionuclides) to engineered antibody fragments. In collaboration with Mark Kieran (DFCI), we are evaluating new imaging agents targeted to the vitronectin receptor for directly monitoring clinical response to anti-angiogenesis therapy.

Publications

• Kiani S, Staples RJ, Packard AB.A lariat-functionalized copper(II) diimine-dioxime complex.Acta Crystallogr C 2002 Dec;58(Pt 12):m593-5.
  12466608
• Packard AB, Kronauge JF, Barbarics E, Kiani S, Treves ST.Synthesis and biodistribution of a Lipophilic 64Cu-labeled monocationic Copper(II) complex.Nucl Med Biol 2002 Apr;29(3):289-94.
  11929697
• Packard AB, Kronauge JF, Day PJ, Treves ST.Synthesis and biodistribution of 64Cu-labeled monocationic diiminedioxime copper(II) complexes.Nucl Med Biol 1998 Aug;25(6):531-7.
  9751419